ES2074429T3 - Derivados de fluorocitidina, su preparacion y preparados medios que los contienen. - Google Patents

Derivados de fluorocitidina, su preparacion y preparados medios que los contienen.

Info

Publication number
ES2074429T3
ES2074429T3 ES88118515T ES88118515T ES2074429T3 ES 2074429 T3 ES2074429 T3 ES 2074429T3 ES 88118515 T ES88118515 T ES 88118515T ES 88118515 T ES88118515 T ES 88118515T ES 2074429 T3 ES2074429 T3 ES 2074429T3
Authority
ES
Spain
Prior art keywords
derivatives
fluorocitidine
contain
preparation
prepared means
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88118515T
Other languages
English (en)
Inventor
Morio Fujiu
Hideo Ishitsuka
Masanori Miwa
Isao Imperial Higashihak Umeda
Kazuteru Yokose
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2074429T3 publication Critical patent/ES2074429T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

LOS DERIVADOS DE 5 - DEOXI - 5 - FLUORCITIDINA DE FORMULA GENERAL(I) DONDE R1, R2 Y R3 SON, INDEPENDIENTEMENTE, H O UN GRUPO FACILMENTE SEPARABLE BAJO CONDICIONES FISIOLOGICAS, CON LA CONDICION DE QUE AL MENOS UNO DE LOS RESTOS R1, R2 Y R3 SEA UN GRUPO FACILMENTE SEPARABLE BAJO CONDICIONES FISIOLOGICAS, ASI COMO HIDRATOS O SOLVATOS DE ESTOS COMPUESTOS TIENEN EFECTO ANTITUMORAL. SE PUEDEN OBTNER PARTIENDO DE COMPUESTOS CORRESPONDIENTES DE LA FORMULA I, DONDE R1, R2 Y R3 REPRESENTAN H, O GRUPOS PROTECTORES DE N U O.
ES88118515T 1987-11-17 1988-11-07 Derivados de fluorocitidina, su preparacion y preparados medios que los contienen. Expired - Lifetime ES2074429T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP87116926 1987-11-17

Publications (1)

Publication Number Publication Date
ES2074429T3 true ES2074429T3 (es) 1995-09-16

Family

ID=8197450

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88118515T Expired - Lifetime ES2074429T3 (es) 1987-11-17 1988-11-07 Derivados de fluorocitidina, su preparacion y preparados medios que los contienen.

Country Status (34)

Country Link
US (1) US4966891A (es)
EP (1) EP0316704B1 (es)
JP (1) JPH0678350B2 (es)
KR (1) KR970000241B1 (es)
CN (1) CN1022688C (es)
AR (1) AR247217A1 (es)
AT (1) ATE124951T1 (es)
AU (1) AU619220B2 (es)
CA (1) CA1327358C (es)
CS (1) CS274486B2 (es)
DE (2) DE10199027I2 (es)
DK (1) DK170893B1 (es)
DZ (1) DZ1270A1 (es)
ES (1) ES2074429T3 (es)
FI (1) FI89804C (es)
GR (1) GR3017686T3 (es)
HU (1) HU199866B (es)
IE (1) IE883430L (es)
IL (1) IL88363A0 (es)
IS (1) IS1895B (es)
LT (1) LT2185B (es)
LU (1) LU90769I2 (es)
LV (1) LV5624A3 (es)
MC (1) MC1992A1 (es)
MX (1) MX173347B (es)
NL (1) NL300045I2 (es)
NO (2) NO171167C (es)
NZ (1) NZ226923A (es)
PH (1) PH25641A (es)
PT (1) PT89009B (es)
SU (1) SU1736342A3 (es)
UA (1) UA19333A (es)
YU (1) YU47122B (es)
ZA (1) ZA888428B (es)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258360B1 (en) * 1989-05-04 2001-07-10 Igen International, Inc. Prodrugs activated by targeted catalytic proteins
US5527782A (en) * 1990-03-13 1996-06-18 Acic (Canada) Inc. 5-halo-2,3'-O-cyclocytidines
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
TW254946B (es) * 1992-12-18 1995-08-21 Hoffmann La Roche
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
IT1291983B1 (it) * 1997-05-23 1999-01-25 Pro Bio Sint Srl Prodcedimento per la preparazione di un derivato della desossiuridina
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
EP0882734B1 (en) * 1997-06-02 2009-08-26 F. Hoffmann-La Roche Ag 5'-Deoxy-cytidine derivatives
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20010051348A1 (en) * 2000-01-28 2001-12-13 Lee Chee Wee Novel ligands and methods for preparing same
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
EP2316469A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
US6774758B2 (en) * 2002-09-11 2004-08-10 Kalyan P. Gokhale Low harmonic rectifier circuit
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
WO2004105747A1 (en) * 2003-05-20 2004-12-09 Aronex Pharmaceuticals, Inc Combination chemotherapy comprising capecitabine and a liposomal platinum complex
CN101128472B (zh) * 2003-12-22 2012-03-14 霍夫曼-拉罗奇有限公司 制备氟胞苷衍生物的方法
BRPI0507734A (pt) * 2004-02-18 2007-07-10 Astrazeneca Ab composto ou um sal, pró-droga ou solvato do mesmo, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto
ES2322709T3 (es) * 2004-02-18 2009-06-25 Astrazeneca Ab Derivados de benzamida y su uso como agentes activadores de la glucocinasa.
CN100383128C (zh) * 2004-02-23 2008-04-23 上海迪赛诺医药发展有限公司 N4－氧羰基胞嘧啶衍生物及制备方法与应用
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
KR101061850B1 (ko) 2004-09-08 2011-09-02 삼성전자주식회사 박막 트랜지스터 표시판 및 그 제조방법
GB0421294D0 (en) * 2004-09-24 2004-10-27 Angiogene Pharm Ltd Bioreductively-activated prodrugs
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
MX2007004560A (es) 2004-10-16 2007-06-08 Astrazeneca Ab Proceso para hacer compuestos de fenoxi benzamida.
WO2006084058A2 (en) 2005-02-03 2006-08-10 The General Hospital Corporation Method for treating gefitinib resistant cancer
NO322682B1 (no) * 2005-03-18 2006-11-27 Clavis Pharma Asa Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer
JP2008534548A (ja) * 2005-04-01 2008-08-28 エフ．ホフマン−ラ ロシュ アーゲー カペシタビンの投与のための方法
EP1891069A1 (en) * 2005-05-24 2008-02-27 AstraZeneca AB 2-phenyl substituted imidazol [4,5b]pyridine/ pyrazine and purine derivatives as glucokinase modulators
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
BRPI0622262A2 (pt) 2005-07-09 2011-08-09 Astrazeneca Ab composto, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto
WO2007007040A1 (en) * 2005-07-09 2007-01-18 Astrazeneca Ab 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
EP2027113A1 (en) * 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
CN100569790C (zh) * 2005-07-15 2009-12-16 上海奥锐特国际贸易有限公司 合成n4-酰基-5＇-脱氧-5-氟胞苷衍生物的方法
ATE546148T1 (de) * 2005-07-21 2012-03-15 Nuvo Res Ag Stabilisierte chlorit-lösungen in kombination mit fluorpyrimidinen zur krebsbehandlung
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
RU2451524C2 (ru) 2005-11-04 2012-05-27 Вайет Противоопухолевые комбинации с ингибиторами mtor, герцептином и/или hki-272
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
TW200825063A (en) 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
CL2007003061A1 (es) 2006-10-26 2008-08-01 Astrazeneca Ab Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2.
CN100425617C (zh) * 2006-10-31 2008-10-15 浙江海正药业股份有限公司 一种含氟嘧啶类化合物烷氧羰酰化的方法
AU2007336016A1 (en) 2006-12-21 2008-06-26 Astrazeneca Ab Novel crystalline compound useful as GLK activator
ITMI20070435A1 (it) 2007-03-05 2008-09-06 Innovate Biotechnology Srl 2',3'-di-o-acil-5-fluoronucleosidi
MX2009011255A (es) * 2007-04-20 2009-11-23 Reddys Lab Ltd Dr Proceso para preparar capecitabina.
WO2008145403A1 (en) * 2007-06-01 2008-12-04 Synthon B.V. Processes related to making capecitabine
WO2009042064A2 (en) 2007-09-21 2009-04-02 Nektar Therapeutics Al, Corporation Oligomer-nucleoside phosphate conjugates
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US20090209754A1 (en) * 2008-01-03 2009-08-20 Macdonald Peter Lindsay Process for the preparation of capecitabine
PT2310011E (pt) 2008-06-17 2013-10-07 Wyeth Llc Combinações antineoplásicas contendo hki-272 e vinorelbina
SMT201700084T1 (it) 2008-08-04 2017-03-08 Wyeth Llc Associazioni antineoplastiche di 4-anilino-3-cianochinoline e capecitabina
EP2324028A2 (en) 2008-08-04 2011-05-25 AstraZeneca AB Therapeutic agents 414
EP2370414A4 (en) * 2008-12-02 2012-11-14 Reddys Lab Ltd Dr PREPARATION OF CAPECITABINE
EP2393472B1 (en) * 2008-12-05 2019-06-05 NanoMed Holdings Pty Ltd Amphiphile prodrugs
CN101787066B (zh) * 2009-01-23 2013-07-31 高峰 阿糖胞苷衍生物及其在抗癌抗肿瘤中的用途
GB0902434D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
GB0902406D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
ES2941894T3 (es) 2009-04-06 2023-05-26 Wyeth Llc Régimen de tratamiento que utiliza neratinib contra el cáncer de mama
AR076220A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivados de pirazol [4,5 - e] pirimidina
WO2010116176A1 (en) * 2009-04-09 2010-10-14 Astrazeneca Ab Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity
CN101875680B (zh) * 2009-04-28 2012-07-25 上海信旗医药科技有限公司 一种核苷类化合物及其制备方法和应用
WO2011010967A1 (en) * 2009-07-23 2011-01-27 Scinopharm Taiwan Ltd. Process for producing flurocytidine derivatives
HUE027831T2 (en) 2010-03-12 2016-11-28 Genzyme Corp Combination therapy for breast cancer
CA2868391A1 (en) 2012-04-02 2013-10-10 Stephane Bancel Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
US20140010861A1 (en) 2012-04-02 2014-01-09 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
JP6666147B2 (ja) * 2012-09-26 2020-03-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 環状エーテルピラゾール−４−イル−ヘテロシクリル−カルボキサミド化合物と使用方法
CN104955458A (zh) 2012-11-07 2015-09-30 Z·索 取代的吉西他滨芳基酰胺类似物和使用所述类似物的治疗方法
HK1220370A1 (zh) 2013-03-15 2017-05-05 Zucai SUO 取代的吉西他滨二环酰胺类似物及使用其治疗的方法
US10138507B2 (en) 2013-03-15 2018-11-27 Modernatx, Inc. Manufacturing methods for production of RNA transcripts
JP2016530294A (ja) 2013-09-03 2016-09-29 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． キメラポリヌクレオチド
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
CN103450301B (zh) * 2013-09-09 2015-09-09 南通大学 法尼基硫代水杨酸-核苷缀合物、其制备方法及其医药用途
MX2016004249A (es) 2013-10-03 2016-11-08 Moderna Therapeutics Inc Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad.
SG11201810947PA (en) * 2016-06-28 2019-01-30 Cellix Bio Private Ltd Compositions and methods for the treatment of cancer
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11034667B2 (en) 2017-01-09 2021-06-15 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
CN110831605A (zh) 2017-04-26 2020-02-21 托马斯·I.·卡尔曼 多靶标的核苷衍生物
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
CA3088287A1 (en) 2018-01-10 2019-07-18 Nucorion Pharmaceuticals, Inc. Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
CN111801339B (zh) * 2018-01-19 2025-06-24 纽科利制药公司 5-氟尿嘧啶化合物
EP3817732A4 (en) * 2018-08-03 2022-06-08 Cellix Bio Private Limited COMPOSITIONS AND METHODS FOR CANCER TREATMENT
CN109651467A (zh) * 2019-01-15 2019-04-19 齐鲁天和惠世制药有限公司 一种卡培他滨杂质及其制备方法
CN114206896B (zh) 2019-07-17 2024-12-17 纽科利制药公司 环状脱氧核糖核苷酸化合物
CN115605492B (zh) 2020-04-21 2025-09-16 配体制药股份有限公司 核苷酸前药化合物
US20230295257A1 (en) 2020-07-24 2023-09-21 Strand Therapeutics Inc. Lipid nanoparticle comprising modified nucleotides
JP2024503000A (ja) 2021-01-08 2024-01-24 ストランド セラピューティクス インコーポレイテッド 発現構築物およびその使用
CA3255274A1 (en) 2022-04-26 2023-11-02 Strand Therapeutics Inc Lipid nanoparticles including a Venezuelan equine encephalitis (VEE) replica and their uses
WO2025193628A2 (en) 2024-03-09 2025-09-18 Aadigen, Llc Compositions for treating cancer with kras mutations and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3404144A (en) * 1965-12-23 1968-10-01 Research Corp 1-beta-d-arabinofuranosyl-5-fluorocytosine compounds
GB1379410A (en) * 1971-06-08 1975-01-02 Upjohn Co 1-beta-d-arabino-furanosyl-n4-alpha-aminoacylcytosines
JPS52153977A (en) * 1976-06-11 1977-12-21 Daikin Ind Ltd Synthesis of 5-fluorouracil and its derivatives
US4071680A (en) * 1976-12-20 1978-01-31 Hoffmann-La Roche Inc. 5'-Deoxy-5-fluoropyrimidine nucleosides
CH633810A5 (en) * 1978-01-01 1982-12-31 Hoffmann La Roche Novel nucleosides and process for their preparation
FR2528311B1 (fr) * 1982-06-14 1985-06-14 Synthelabo Compositions pharmaceutiques a base de xylosides et lyxosides de bases puriques et pyrimidiques
JPS61112093A (ja) * 1984-11-05 1986-05-30 Wakunaga Seiyaku Kk ヌクレオチド誘導体

Also Published As

Publication number Publication date
YU47122B (sh) 1994-12-28
PT89009B (pt) 1993-02-26
HUT48267A (en) 1989-05-29
MX13836A (es) 1993-10-01
PH25641A (en) 1991-08-21
CN1033183A (zh) 1989-05-31
NO171167B (no) 1992-10-26
EP0316704A3 (en) 1990-11-22
EP0316704A2 (de) 1989-05-24
UA19333A (uk) 1997-12-25
NO171167C (no) 1993-02-03
DK170893B1 (da) 1996-03-04
AU2516888A (en) 1989-05-25
ZA888428B (en) 1989-06-28
IE883430L (en) 1989-05-17
FI89804B (fi) 1993-08-13
EP0316704B1 (de) 1995-07-12
NL300045I2 (nl) 2002-01-02
HK1003114A1 (en) 1998-10-09
IS1895B (is) 2003-10-20
CS747588A2 (en) 1990-09-12
AR247217A1 (es) 1994-11-30
CA1327358C (en) 1994-03-01
GR3017686T3 (en) 1996-01-31
JPH0678350B2 (ja) 1994-10-05
LU90769I2 (fr) 2001-07-02
NO885106L (no) 1989-05-18
DE10199027I1 (de) 2001-08-02
NO2001013I2 (no) 2006-05-01
LV5624A3 (lv) 1994-05-10
MC1992A1 (fr) 1989-11-30
PT89009A (pt) 1988-12-01
JPH01153696A (ja) 1989-06-15
US4966891A (en) 1990-10-30
SU1736342A3 (ru) 1992-05-23
ATE124951T1 (de) 1995-07-15
DK640388D0 (da) 1988-11-16
DK640388A (da) 1989-05-18
KR970000241B1 (ko) 1997-01-08
NZ226923A (en) 1990-10-26
CN1022688C (zh) 1993-11-10
FI89804C (fi) 1993-11-25
IL88363A0 (en) 1989-06-30
CS274486B2 (en) 1991-04-11
FI885329A0 (fi) 1988-11-17
NO885106D0 (no) 1988-11-16
LT2185B (lt) 1993-10-15
NL300045I1 (nl) 2001-08-01
YU209188A (en) 1990-08-31
IS3412A7 (is) 1989-05-18
DE10199027I2 (de) 2002-01-31
AU619220B2 (en) 1992-01-23
KR890008162A (ko) 1989-07-10
MX173347B (es) 1994-01-03
DZ1270A1 (fr) 2004-09-13
HU199866B (en) 1990-03-28
DE3854148D1 (de) 1995-08-17
FI885329L (fi) 1989-05-18

Similar Documents

Publication Publication Date Title
ES2074429T3 (es) Derivados de fluorocitidina, su preparacion y preparados medios que los contienen.
ES2150918T3 (es) 1h-imidazo(4,5-c)quinolin-4-aminas 1-sustituidas; compuestos intermedios y composiciones farmaceuticas.
CO4700455A1 (es) Derivados tetraciclicos y proceso para su preparacion
ES2118992T3 (es) Derivados ciclicos, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
ES474592A1 (es) Procedimiento para la preparacion de derivados de imidazoli-nina
ES2059207T3 (es) Procedimiento para la preparacion de derivados del taxano, nuevos derivados obtenidos y composiciones farmaceuticas que les contienen.
ES2149215T3 (es) Bencilaminoquinuclidinas sustituidas como antagonistas de la sustancia p.
JPS5412381A (en) N-alkylpiperidine derivative
ES2066808T3 (es) Derivados de quinoleina, su produccion y uso.
AT370763B (de) Kohlensuspension, enthaltend pulverisierte kohle, wasser und dispergierungsmittel, sowie verfahren zur herstellung derselben
ES8102131A1 (es) Procedimiento para preparar una composicion oral que com- prende un compuesto de 2-penem
FI874975A0 (fi) Antioxidanta kompositioner och foerfarande foer deras framstaellning.
MX9305805A (es) Aroiloxicarboxamidas yodados.
ES2009785B3 (es) Procedimiento para preparar derivados de tioxantona.
ES2059416T3 (es) 1,4-dihidropiridina-enantiomeros.
MX168030B (es) Procedimiento para la preparacion de derivados de alcano y alcoxialcano
DE3661913D1 (en) Derivatives of 2,3-dihydro-benzofurane, processes for their preparation and pharmaceutical compositions containing them
ES2043725T3 (es) Aminofenil-carbamatos substituidos.
ES2095068T3 (es) Peroxicarbonatos polimericos y procedimiento para prepararlos.
GR64937B (en) Method for the preparation of derivatives of benzimidazole which containing sulphur
ES2057322T3 (es) Derivados de amida de aminoacido substituidos, su fabricacion y uso.
ES2075004T3 (es) Derivados de pirimidina, procedimientos para su produccion y composiciones herbicidas que los contienen.
NO803245L (no) Fremgangsmaate ved fremstilling av cyclisk hexapeptid somatostatinanaloger.
ES2038684T3 (es) Procedimiento de preparacion de derivados de octahidroindol y de compuestos intermedios de su preparacion.
SE8006953L (sv) Heterocykliska foreningar

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 316704

Country of ref document: ES

SPCF Request for supplementary protection certificate filed

Free format text: CAPECITABINE (XELODA)

Spc suppl protection certif: C200100017

Filing date: 20010628

SPCG Supplementary protection certificate granted

Free format text: CAPECITABINE (XELODA)

Spc suppl protection certif: C200100017

Filing date: 20010628

Expiry date: 20131107

Effective date: 20031211